






## SPRINT® Peripheral Nerve Stimulation (PNS) System Overview

The SPRINT Peripheral Nerve Stimulation (PNS) System is the only percutaneous PNS device FDA cleared for both chronic and acute pain, including post-operative and post-traumatic pain. SPRINT is a minimally invasive and non-opioid neurostimulation device that is prescribed by a physician and placed in the back or extremities to deliver mild electrical pulses to a targeted peripheral nerve for a treatment period of up to 60 days. In studies, SPRINT has demonstrated significant and sustained pain relief in most patients for at least 12 months.

### Components:

<p><b>The SPRINT MicroLead™</b> The SPRINT MicroLead is constructed using a thin, coiled wire approximately the size of a hair. It is implanted by the physician in an outpatient setting, typically under image-guidance, using a needle-based introducer. The MicroLead delivers mild electrical pulses targeted to a specific peripheral nerve.</p>	
<p><b>Pulse Generator</b> The MicroLead is attached to an external pulse generator that is worn on the body.</p>	
<p><b>Remote</b> The patient uses a small Bluetooth enabled remote control to adjust the stimulation.</p>	

### How it works:

Pain is perceived by the brain from signals sent up the spinal cord from peripheral nerves. Rather than stimulating the spinal cord, SPRINT is designed to target the peripheral nerve delivering tiny electrical pulses to interrupt those pain messages and decrease pain symptoms.

The SPRINT PNS System works by implanting a thin leadwire called a MicroLead™, typically under image guidance, targeting a peripheral nerve. The placement does not require surgery or incisions and is typically conducted as an outpatient procedure performed under local anesthesia. The MicroLead is attached to a

wearable external generator that sends tiny electrical pulses to the nerve for up to 60 days. Patients can adjust the stimulation level as desired using a handheld Bluetooth-enabled remote control. After 60 days, the MicroLead is withdrawn in the physician's office.

Physicians have prescribed the SPRINT system to treat multiple pain conditions including post-amputation pain, inoperable shoulder and knee joint pain, chronic low back pain, complex regional pain syndrome (CRPS), and post-operative pain following joint replacement and surgical reconstruction (partial listing).

SPRINT is the most highly researched PNS system available with over 25 peer-reviewed publications. In multiple studies, the SPRINT PNS System has demonstrated significant and sustained improvements in pain and function in most patients, for at least 12 months. Several post-market clinical trials are underway.

#### SPRINT PNS milestones

July 2016	SPRINT PNS is FDA-cleared, making it the first and only percutaneous PNS system FDA cleared to treat both chronic and acute pain.
July 2018	SPRINT® <i>endura</i> ™ and SPRINT® <i>extensa</i> ™ are FDA-cleared allowing a single and a dual lead option, respectively. SPRINT® <i>extensa</i> ™ is the only dual lead capable PNS platform.
October 2018	Department of Defense awards SPR Therapeutics \$10M in grants and awards, bringing total to more than \$30M from DoD and NIH, to support further clinical validation and advancement of SPR's neurostimulation technology for pain.
April 2019	Data published in <a href="#">Regional Anesthesia and Pain Medicine</a> demonstrated that SPRINT's short-term PNS therapy may provide enduring clinically significant pain relief, reduce opioid use and improve quality of life in patients with post-amputation pain, a type of neuropathic pain believed by many to be the most difficult to treat.

The SPRINT® Peripheral Nerve Stimulation (PNS) System is indicated for up to 60 days in the back and/or extremities for: (i) symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) symptomatic relief of post-traumatic pain; (iii) symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the craniofacial region. Important safety information can be found [here](#).  
Rx Only

#### Company Contact:

Mark Stultz

[MStultz@SprTherapeutics.com](mailto:MStultz@SprTherapeutics.com)

612-770-0390

#### Media Contact:

Helen Shik

[ShikPR@SprTherapeutics.com](mailto:ShikPR@SprTherapeutics.com)

617-510-4373